These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22037880)

  • 1. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G; Zhan Y; Wang H; Li W
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
    Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
    Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3.
    Jin X; Cai L; Wang C; Deng X; Yi S; Lei Z; Xiao Q; Xu H; Luo H; Sun J
    Cell Death Dis; 2018 Feb; 9(3):318. PubMed ID: 29476051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
    Dzieran J; Beck JF; Sonnemann J
    Cancer Sci; 2008 Aug; 99(8):1685-92. PubMed ID: 18754884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
    Karpel-Massler G; Ramani D; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2016 Jun; 7(23):33512-28. PubMed ID: 27172899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.
    Kock N; Kasmieh R; Weissleder R; Shah K
    Neoplasia; 2007 May; 9(5):435-42. PubMed ID: 17534449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
    Greenberg EF; McColl KS; Zhong F; Wildey G; Dowlati A; Distelhorst CW
    Cell Death Dis; 2015 Dec; 6(12):e2034. PubMed ID: 26720343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
    Zhang X; Ling MT; Wong YC; Wang X
    Cancer Sci; 2007 Mar; 98(3):308-14. PubMed ID: 17214747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy.
    García-Aranda M; Pérez-Ruiz E; Redondo M
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544835
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic targeting of TRAIL death receptors.
    Di Cristofano F; George A; Tajiknia V; Ghandali M; Wu L; Zhang Y; Srinivasan P; Strandberg J; Hahn M; Sanchez Sevilla Uruchurtu A; Seyhan AA; Carneiro BA; Zhou L; Huntington KE; El-Deiry WS
    Biochem Soc Trans; 2023 Feb; 51(1):57-70. PubMed ID: 36629496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.
    Montinaro A; Walczak H
    Cell Death Differ; 2023 Feb; 30(2):237-249. PubMed ID: 36195672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3-mimetics: recent developments in cancer therapy.
    Townsend PA; Kozhevnikova MV; Cexus ONF; Zamyatnin AA; Soond SM
    J Exp Clin Cancer Res; 2021 Nov; 40(1):355. PubMed ID: 34753495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol Derivative, Trans-3, 5, 4'-Trimethoxystilbene Sensitizes Osteosarcoma Cells to Apoptosis via ROS-Induced Caspases Activation.
    Feng Y; Clayton J; Yake W; Li J; Wang W; Winne L; Hong M
    Oxid Med Cell Longev; 2021; 2021():8840692. PubMed ID: 33833855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation.
    Hong M; Li J; Li S; M Almutairi M
    Cells; 2019 Nov; 8(11):. PubMed ID: 31752383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAILblazing Strategies for Cancer Treatment.
    Kretz AL; Trauzold A; Hillenbrand A; Knippschild U; Henne-Bruns D; von Karstedt S; Lemke J
    Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30935038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL pathway targeting therapeutics.
    Ralff MD; El-Deiry WS
    Expert Rev Precis Med Drug Dev; 2018; 3(3):197-204. PubMed ID: 30740527
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Li GM; Liang CJ; Zhang DX; Zhang LJ; Wu JX; Xu YC
    Chin Med J (Engl); 2018 Oct; 131(19):2320-2331. PubMed ID: 30246718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.
    Fakiruddin KS; Ghazalli N; Lim MN; Zakaria Z; Abdullah S
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Liang C; Xu Y; Li G; Zhao T; Xia F; Li G; Zhang D; Wu J
    Onco Targets Ther; 2017; 10():417-428. PubMed ID: 28176915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells.
    Zheng R; You Z; Jia J; Lin S; Han S; Liu A; Long H; Wang S
    Mol Med Rep; 2016 Feb; 13(2):1570-6. PubMed ID: 26707143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.